PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsYoung breast cancer patients forgo tamoxifen over fertility concerns

BioNews

Young breast cancer patients forgo tamoxifen over fertility concerns

Published 28 August 2015 posted in News and appears in BioNews 817

Author

Kirsty Oswald

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.

Researchers in the USA have found that fertility concerns may be contributing to low tamoxifen use and discontinuation of the drug among reproductive-age breast cancer patients...

Researchers in the USA have found that fertility concerns may be contributing to low tamoxifen use and discontinuation of the drug among reproductive-age breast cancer patients.

Tamoxifen is recommended for five years following treatment for certain types of breast cancer. Previous research has shown that the drug reduces the risk of disease recurrence by 47 percent and the risk of death by 26 percent.

While the drug is not thought to damage fertility itself, women must stop taking it if they wish to become pregnant because it is teratogenic.

Researchers Dr Jacqueline Jeruss, from the University of Michigan in Ann Arbor, and colleagues found that 35 percent of patients who either refused to take tamoxifen or discontinued treatment before five years cited fertility concerns as the reason.

'With this information, what we hope we will now be able to accomplish is a targeted intervention that is in line with current guidelines... that state that patients should be referred to a fertility specialist at the earliest possible time point in their diagnosis,' Dr Jeruss told MedPage Today.

In the study, the researchers reviewed the medical notes of 515 premenopausal women with breast cancer for whom tamoxifen was recommended.

They found that, overall, 13 percent of patients declined tamoxifen and a further 16 percent stopped treatment before five years.

The most common reason for refusing or discontinuing tamoxifen was concern or experience of side effects, recorded for 36 and 69 percent of these patients, respectively.

However, the researchers also found that women who expressed at the time of diagnosis that they wanted to preserve their fertility were five times more likely to decline tamoxifen than other women. These women were also 78 percent more likely to discontinue tamoxifen within five years if they did begin taking it.

These findings were also confirmed when then researchers conducted telephone interviews with 88 patients who did not start or discontinued therapy, with 35 percent citing fertility concerns as their primary reason.

'Our study points toward the importance of fertility to young breast cancer patients,' commented
Dr Jeruss. 'We need to find a way to bridge the gap between this patient survivorship goal and our concerns as physicians to facilitate the best treatment possible for our patients.'

Currently, women who want to become pregnant while taking tamoxifen are advised to take the treatment for two years before having a break to have a child. However, it is currently unclear what effect that has on the effectiveness of the drug. A large, international trait, known as POSITIVE, is currently underway to attempt to resolve this question.

Related Articles

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
5 April 2016 • 2 minutes read

Girl childhood cancer survivors less likely than boys to become infertile

by Isobel Steer

A large study has confirmed that modern chemotherapy regimes for childhood cancers can adversely affect both male and female fertility...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
23 October 2015 • 2 minutes read

Stem cells show potential to restore fertility after chemotherapy

by Dr Nicoletta Charolidi

A stem-cell therapy in mice shows promise for reversing infertility in women who have received cancer treatment...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
25 September 2015 • 2 minutes read

Mutations may predict breast cancer relapse

by Neil Stoker

Researchers have identified genetic differences in breast cancers that relapse and those that do not, suggesting that the finding could be used to help doctors identify patients most at risk of their cancer returning...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
6 March 2015 • 2 minutes read

Drug helps young breast cancer patients avoid early menopause

by Meghna Kataria

A drug can reduce the risk of infertility and early menopause in women undergoing chemotherapy for certain early stage breast cancers...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
21 November 2014 • 2 minutes read

5,000 young breast cancer patients 'miss out on fertility care' in UK every year

by Isobel Steer

The majority of young breast cancer patients are not being referred for treatment which could preserve their fertility after chemotherapy, says a UK charity...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
Comment
22 September 2014 • 3 minutes read

Commissioning decisions reveal the trivialisation of infertility

by Vicky Whitehead

In the UK, clinical commissioners seem to view the national recommendations on fertility treatment as a sort of à-la-carte menu from which they can pick and choose; altering the definition of a cycle, the age requirements, the number of cycles available, and the access criteria at will...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
25 July 2014 • 2 minutes read

Mid Essex: Only HIV and cancer patients could be eligible for IVF

by Ruth Retassie

Mid Essex Clinical Commissioning Group has proposed to limit access to IVF to cancer patients and HIV-positive men under its options for reform to the funding of its fertility services....

Leave a Reply Cancel reply

You must be logged in to post a comment.

« IVF availability linked to motherhood delay

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856